



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/808,832	03/15/2001	Robert A. Copeland	PH-7134

CONFIRMATION NO. 5618

24348
 Dupont Pharmaceuticals Company
 Legal Department - Patents
 1007 Market Street
 Wilmington, DE 19898

FORMALITIES LETTER



OC000000006056391

Date Mailed: 05/09/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

A handwritten signature, appearing to be "T. M.", is written above a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



Atty. Dkt. No. PH-7134

J for \$ #4
Box Seg
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Copeland)	
)	
U.S. Serial No.:	09/808,832)	Examiner: Not Yet Assigned
)	
Filed:	03/15/01)	Art Unit: Not Yet Assigned
)	
For:	Peptidase-Cleavable, Targeted Antineoplastic)	
	Drugs And Their Therapeutic Use)	

Hon. Commissioner of
Patents and Trademarks
Washington, D.C. 20231

RESPONSE TO NOTICE TO FILE MISSING PARTS

This communication is in response to the Notice to File Missing Parts mailed May 9, 2001. Applicants respectfully request reconsideration in view of the following remarks.

REMARKS

In response to the Notice to File Missing Parts the Applicants are submitting herewith a signed Declaration. Authorization is also given to charge a surcharge in the amount of \$130.00 for the late filing of the signed Declaration to Deposit Account 04-1928 (E.I. du Pont de Nemours and Company).

In addition, Applicants have been informed that while a copy of the Sequence Listing in computer readable form has been submitted, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823 as indicated on the marked-up "Raw Sequence Listing."

A copy of a marked-up "Raw Sequence Listing" is enclosed here along with this response as required by the Notice to File Missing Parts. Also, Applicants are providing the U.S. Patent Office the following:


- (1) An substitute computer readable form (CRF) copy of the "Sequence Listing";
- (2) An substitute paper copy of the "Sequence Listing", as well as this amendment directing its entry into the specification (stated above); and
- (3) A statement that the content of the paper and computer readable copies are the same and includes no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) (following below).

The Applicants direct the entry of the substitute CRF copy of the "Sequence Listing" along with a substitute paper copy of same into the specification. Applicants further state that the contents of the paper and CRF copies of the "Sequence Listing" are the same and include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

Applicants maintain that the application is now in condition for substantive examination, and early notice to that effect is respectfully requested. No fee is deemed necessary in connection with this response's filing other than the \$130.00 surcharge required in connection with the late filing of the signed Declaration. However, if any other fee is deemed necessary, authorization is hereby given to charge the amount of such a fee to Deposit Account No. 04-1928.

6-26-01
(Date)

Respectfully submitted,


Kalim S. Fuzail
Attorney for Applicant
Registration No. 45,805
Telephone: 302-992-3215

PH-7134 Response (June 2001).doc




Certificate of Mailing under 37 CFR 1.8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:**Robert A. Copeland et al****CASE NO.: PH-7134****APPLICATION NO.: 09/808,832****GROUP ART UNIT: 1614****FILED: MARCH 15, 2001****EXAMINER: UNKNOWN****FOR: PEPTIDE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR
THERAPEUTIC USE**


I hereby certify that this correspondence, a **Notice to File Missing Parts, Fee Transmittal Sheet, Declaration (3 pages), Power of Attorney (10 pages), Marked-Up Copy of Sequence List, Disc, PTO Copy of Notice to File Missing Parts, and Sequence Listing**, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231


Date
Signature
Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



FEES TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$ 130.00)

Complete if Known	
Application Number	09/808,832
Filing Date	March 15, 2001
First Named Inventor	Copeland et al
Examiner Name	Unknown
Group / Art Unit	1614
Attorney Docket No.	PH-7134

METHOD OF PAYMENT (check one)

1. The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number	04-1928
Deposit Account Name	DuPont Pharmaceuticals Company

Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17
 Applicant claims small entity status. See 37 CFR 1.27

2. Payment Enclosed:
 Check Credit card Money Order Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Entity Fee (\$)	Small Entity Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES

Total Claims	-20**	=	Extra Claims	X	Fee from below	=	Fee Paid
Independent Claims	-3**	=	0	X		=	0
Multiple Dependent				X		=	0

Large Entity Fee Code	Entity Fee (\$)	Small Entity Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
103	18	203	9	Claims in excess of 20	
102	80	202	40	Independent claims in excess of 3	
104	270	204	135	Multiple dependent claim, if not paid	
109	80	209	40	** Reissue independent claims over original patent	
110	18	210	9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$)

3. ADDITIONAL FEES

Large Entity Fee Code	Entity Fee (\$)	Small Entity Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	130
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	130	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))	
179 (RCE)	710	279	355	Request for Continued Examination	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify) (\$)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 130.00)

**or number previously paid, if greater; For Reissues, see above

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Kalim S. Fuzail	Registration No. Attorney/Agent	45,805	Telephone	302-992-3215
Signature				Date	6-26-01

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

BIOTECHNOLOGY
SYSTEMS
BRANCH

**RAW SEQUENCE LISTING
ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/808,832

Source: OIPE

Date Processed by STIC: 3/30/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY.

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (W.I.P.O.) Standard ST/25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K compliant. Checker allows public users to check sequence listings in Computer Readable Form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be downloaded from the USPTO website at the following address:



Raw Sequence Listing Error Summary

SERIAL NUMBER: 09/808,832

	<u>ERROR DETECTED</u>	<u>SUGGESTED CORRECTION</u>
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE		
1	Wrapped Nucleic	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping".
2	Wrapped Aminos	The amino acid number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping".
3	Incorrect Line Length	The rules require that a line not exceed 72 characters in length. This includes spaces.
4	Misaligned Amino Acid Numbering	The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
5	Non-ASCII	This file was not saved in ASCII (DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
5	Variable Length	Sequence(s) ____ contain n's or Xaa's which represented more than one residue. As per the rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.
7	PatentIn ver. 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
8	Skipped Sequences (OLD RULES)	Sequence(s) ____ missing. If intentional, please use the following format for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS") (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: This sequence is intentionally skipped Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
9	Skipped Sequences (NEW RULES)	Sequence(s) ____ missing. If intentional, please use the following format for each skipped sequence. <210> sequence id number <400> sequence id number 000
10	Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Use of <220> to <223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
11	Use of <213>Organism (NEW RULES)	Sequence(s) ____ are missing this mandatory field or its response.
12	Use of <220>Feature (NEW RULES)	Sequence(s) ____ are missing the <220>Feature and associated headings. Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial Sequence" or "Unknown" Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
13	PatentIn ver. 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other means to copy file to floppy disk.



OIPE

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001
TIME: 15:15:26

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03302001\I808832.raw

Does Not Comply
Corrected Diskette Needed

ppr 1-5

3 <110> APPLICANT: DuPont Pharmaceuticals Company
 5 <120> TITLE OF INVENTION: Peptidase-cleavable, targeted antineoplastic drugs and their
 therapeutic use
 6 <130> FILE REFERENCE: PH-7134
 10 <140> CURRENT APPLICATION NUMBER: US/09/808,832
 10 <141> CURRENT FILING DATE: 2001-03-15
 10 <150> PRIOR APPLICATION NUMBER: 60/189,387
 11 <151> PRIOR FILING DATE: 2000-03-15
 13 <160> NUMBER OF SEQ ID NOS: 210
 15 <170> SOFTWARE: PatentIn version 3.0
 17 <210> SEQ ID NO: 1
 18 <211> LENGTH: 5
 19 <212> TYPE: PRT
 20 <213> ORGANISM: Artificial
 22 <220> FEATURE:
 23 <223> OTHER INFORMATION: no comment
 25 <220> FEATURE:
 26 <221> NAME/KEY: MOD_RES
 27 <222> LOCATION: (1)..(1)
 28 <223> OTHER INFORMATION: 4-methoxy-benzenesulfonyl-beta-alanine
 31 <220> FEATURE:
 32 <221> NAME/KEY: MOD_RES
 33 <222> LOCATION: (3)..(3)
 34 <223> OTHER INFORMATION: homophenylalanine
 37 <400> SEQUENCE: 1
 39 Xaa Gly Xaa Tyr Leu
 40 1 5
 42 <210> SEQ ID NO: 2
 43 <211> LENGTH: 5
 44 <212> TYPE: PRT
 45 <213> ORGANISM: Artificial
 47 <220> FEATURE:
 48 <223> OTHER INFORMATION: no comment
 50 <220> FEATURE:
 51 <221> NAME/KEY: MOD_RES
 52 <222> LOCATION: (1)..(1)
 53 <223> OTHER INFORMATION: 1,2-C6H4(CO)2-histidine
 56 <220> FEATURE:
 57 <221> NAME/KEY: MOD_RES
 58 <222> LOCATION: (3)..(3)
 59 <223> OTHER INFORMATION: homophenylalanine
 62 <400> SEQUENCE: 2
 64 Xaa Gly Xaa Tyr Leu
 65 1 5
 67 <210> SEQ ID NO: 3
 68 <211> LENGTH: 5
 69 <212> TYPE: PRT

per 1.823 of Sequence Rules, valid response
 is
 Artificial Sequence
 genetice material - see item 12 on Error
 summary
 sheet

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001
TIME: 15:15:26

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03302001\I808832.raw

70 <213> ORGANISM: Artificial
72 <220> FEATURE:
73 <223> OTHER INFORMATION: no comment
75 <220> FEATURE:
76 <221> NAME/KEY: MOD_RES
77 <222> LOCATION: (1)..(1)
78 <223> OTHER INFORMATION: acetyl-proline
81 <400> SEQUENCE: 3
83 Xaa Leu Gly Leu Leu
84 1 5
86 <210> SEQ ID NO: 4
87 <211> LENGTH: 5
88 <212> TYPE: PRT
89 <213> ORGANISM: Artificial
91 <220> FEATURE:
92 <223> OTHER INFORMATION: no comment
94 <220> FEATURE:
95 <221> NAME/KEY: MOD_RES
96 <222> LOCATION: (1)..(1)
97 <223> OTHER INFORMATION: acetyl-proline
100 <400> SEQUENCE: 4
102 Xaa Leu Gly Leu Leu
103 1 5
105 <210> SEQ ID NO: 5
106 <211> LENGTH: 5
107 <212> TYPE: PRT
108 <213> ORGANISM: Artificial
110 <220> FEATURE:
111 <223> OTHER INFORMATION: no comment
113 <220> FEATURE:
114 <221> NAME/KEY: MOD_RES
115 <222> LOCATION: (2)..(2)
116 <223> OTHER INFORMATION: beta alanine
119 <220> FEATURE:
120 <221> NAME/KEY: MOD_RES
121 <222> LOCATION: (1)..(1)
122 <223> OTHER INFORMATION: acetyl-proline
125 <400> SEQUENCE: 5
127 Xaa Xaa Gly Leu Leu
128 1 5
130 <210> SEQ ID NO: 6
131 <211> LENGTH: 5
132 <212> TYPE: PRT
133 <213> ORGANISM: Artificial
135 <220> FEATURE:
136 <223> OTHER INFORMATION: no comment
138 <220> FEATURE:
139 <221> NAME/KEY: MOD_RES
140 <222> LOCATION: (2)..(2)

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001
TIME: 15:15:26

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03302001\I808832.raw

141 <223> OTHER INFORMATION: 4-aminobutyric acid
144 <220> FEATURE:
145 <221> NAME/KEY: MOD_RES
146 <222> LOCATION: (1)..(1)
147 <223> OTHER INFORMATION: acetyl-proline
150 <400> SEQUENCE: 6
152 Xaa Xaa Gly Leu Leu
153 1 5
155 <210> SEQ ID NO: 7
156 <211> LENGTH: 5
157 <212> TYPE: PRT
158 <213> ORGANISM: Artificial
160 <220> FEATURE:
161 <223> OTHER INFORMATION: no comment
163 <220> FEATURE:
164 <221> NAME/KEY: MOD_RES
165 <222> LOCATION: (2)..(2)
166 <223> OTHER INFORMATION: cyclohexylalanine
169 <220> FEATURE:
170 <221> NAME/KEY: MOD_RES
171 <222> LOCATION: (1)..(1)
172 <223> OTHER INFORMATION: acetyl-proline
175 <400> SEQUENCE: 7
177 Xaa Xaa Gly Leu Leu
178 1 5
180 <210> SEQ ID NO: 8
181 <211> LENGTH: 5
182 <212> TYPE: PRT
183 <213> ORGANISM: Artificial
185 <220> FEATURE:
186 <223> OTHER INFORMATION: no comment
188 <400> SEQUENCE: 8
190 Pro Leu Gly Leu Leu
191 1 5
193 <210> SEQ ID NO: 9
194 <211> LENGTH: 5
195 <212> TYPE: PRT
196 <213> ORGANISM: Artificial
198 <220> FEATURE:
199 <223> OTHER INFORMATION: no comment
201 <220> FEATURE:
202 <221> NAME/KEY: MOD_RES
203 <222> LOCATION: (1)..(1)
204 <223> OTHER INFORMATION: MeOCH₂CH₂OCH₂(=O)-proline
207 <400> SEQUENCE: 9
209 Xaa Leu Gly Leu Leu
210 1 5
212 <210> SEQ ID NO: 10
213 <211> LENGTH: 5

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001
TIME: 15:15:26

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03302001\I808832.raw

214 <212> TYPE: PRT
215 <213> ORGANISM: Artificial
217 <220> FEATURE:
218 <223> OTHER INFORMATION: no comment
220 <220> FEATURE:
221 <221> NAME/KEY: MOD_RES
222 <222> LOCATION: (1)..(1)
223 <223> OTHER INFORMATION: MeOCH2CH2OCH2CH2OCH2C(=O)-proline
226 <400> SEQUENCE: 10
OK 228 Xaa Leu Gly Leu Leu
229 1 5
231 <210> SEQ ID NO: 11
232 <211> LENGTH: 5
233 <212> TYPE: PRT
234 <213> ORGANISM: Artificial
236 <220> FEATURE:
237 <223> OTHER INFORMATION: no comment
239 <220> FEATURE:
240 <221> NAME/KEY: MOD_RES
241 <222> LOCATION: (1)..(1)
242 <223> OTHER INFORMATION: H2NCH2CH2N(CH2CH2)2NCH2C(=O)-proline
245 <400> SEQUENCE: 11
OK 247 Xaa Leu Gly Leu Leu
248 1 5
250 <210> SEQ ID NO: 12
251 <211> LENGTH: 5
252 <212> TYPE: PRT
253 <213> ORGANISM: Artificial
255 <220> FEATURE:
256 <223> OTHER INFORMATION: no comment
258 <220> FEATURE:
259 <221> NAME/KEY: MOD_RES
260 <222> LOCATION: (1)..(1)
261 <223> OTHER INFORMATION: AcHNCH2CH2N(CH2CH2)2NCH2C(=O)-proline
264 <400> SEQUENCE: 12
OK 266 Xaa Leu Gly Leu Leu
267 1 5
269 <210> SEQ ID NO: 13
270 <211> LENGTH: 5
271 <212> TYPE: PRT
272 <213> ORGANISM: Artificial
274 <220> FEATURE:
275 <223> OTHER INFORMATION: no comment
277 <220> FEATURE:
278 <221> NAME/KEY: MOD_RES
279 <222> LOCATION: (1)..(1)
280 <223> OTHER INFORMATION: AcN(CH2CH2)2NCH2C(=O)-proline
283 <400> SEQUENCE: 13
OK 285 Xaa Leu Gly Leu Leu

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001
TIME: 15:15:26

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03302001\I808832.raw

286 1 5
288 <210> SEQ ID NO: 14
289 <211> LENGTH: 4
290 <212> TYPE: PRT
291 <213> ORGANISM: Artificial
293 <220> FEATURE:
294 <223> OTHER INFORMATION: no comment
296 <220> FEATURE:
297 <221> NAME/KEY: MOD_RES
298 <222> LOCATION: (4)..(4)
299 <223> OTHER INFORMATION: O-benzyl-serine
302 <400> SEQUENCE: 14
OK 304 Pro Leu Gly Xaa
305 1
307 <210> SEQ ID NO: 15
308 <211> LENGTH: 4
309 <212> TYPE: PRT
310 <213> ORGANISM: Artificial
312 <220> FEATURE:
313 <223> OTHER INFORMATION: no comment
315 <220> FEATURE:
316 <221> NAME/KEY: MOD_RES
317 <222> LOCATION: (1)..(1)
318 <223> OTHER INFORMATION: acetyl-proline
321 <400> SEQUENCE: 15
OK 323 Xaa Leu Gly Leu
324 1
326 <210> SEQ ID NO: 16
327 <211> LENGTH: 5
328 <212> TYPE: PRT
329 <213> ORGANISM: Artificial
331 <220> FEATURE:
332 <223> OTHER INFORMATION: no comment
334 <220> FEATURE:
335 <221> NAME/KEY: MOD_RES
336 <222> LOCATION: (1)..(1)
337 <223> OTHER INFORMATION: acetyl-glycine
340 <400> SEQUENCE: 16
OK 342 Xaa Pro Leu Gly Leu
343 1 5
345 <210> SEQ ID NO: 17
346 <211> LENGTH: 6
347 <212> TYPE: PRT
348 <213> ORGANISM: Artificial
350 <220> FEATURE:
351 <223> OTHER INFORMATION: no comment
353 <220> FEATURE:
354 <221> NAME/KEY: MOD_RES
355 <222> LOCATION: (1)..(1)

Please correct these errors
in subsequent sequences
too.

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the
Seq. Listing to ensure that a corresponding explanation is presented in the <220> to

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001
TIME: 15:15:27

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03302001\I808832.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application No
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:39 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:64 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:83 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:102 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:127 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:152 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:177 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:209 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:228 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:247 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:266 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:285 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13
L:304 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:323 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15
L:342 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:373 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17
L:398 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18
L:429 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:460 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:491 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21
L:516 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:541 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:566 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:591 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:616 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:26
L:641 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:666 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28
L:691 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29
L:710 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:30
L:729 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
L:748 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
L:773 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:804 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
L:823 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:842 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:861 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:886 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38
L:905 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39
L:924 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:40
L:943 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:41
L:962 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:42
L:981 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:43
L:1000 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:44
L:1019 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:45
L:1038 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46
L:1057 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001

TIME: 15:15:27

Input Set : A:\PTO.txt

Output Set: N:\CRF3\03302001\I808832.raw

::1076 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48
::1095 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:49
::1114 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50
::1133 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51